Cell Therapy Manufacturing and Clinical Comparability: What, How, and When

Cell_Therapy_Manufacturing
Establishing comparability in manufacturing cell therapies is a significant challenge for the field due to the complexity of the products, limited material availability, and inherent donor-to-donor variability. As products progress through their lifecycles, organizations need to focus on their ultimate manufacturing end goal. In addition, commercialization and application of cell therapy products to larger patient populations drive the need to switch from small-scale, manual, or semi-automated single function-based production models to more robust and efficient commercial-scale manufacturing using closed and automated end-to-end platforms.
Watch Now

Spotlight

OTHER ON-DEMAND WEBINARS

Automated, large-scale and GMP-compliant cell manufacturing

on24

Regenerative medicine has become a key focus worldwide and the number of stem cell therapy trials are rapidly increasing every year. Yet, large-scale and GMP-compliant stem cell manufacturing is still a major hurdle for clinical applications across the globe. In this webinar, we will show you how to implement GMP-compliant and scalable manufacturing of different adherent cell types, such as pluripotent stem cells and their derivatives, in the CliniMACS Prodigy® Adherent Cell Culture System.
Watch Now

AlphaLISA and HT-SPR together can help you better understand FcRn biology

Therapeutic discovery and development rely on numerous analytical techniques in order to best position candidate drugs for commercial success. Different analytical technologies are utilized for their respective strengths in maximizing understanding of candidate properties.
Watch Now

Soft Tissue Cancer-IHC Webinar

Merck KGaA

Soft tissue tumors are a broad group of neoplasms that involve the connective tissue of the body. Each year, over 13,000 people in the US are diagnosed with soft tissue sarcomas and over 5,000 people succumb to the malignancy. Because soft tissue sarcomas are very ambiguous and amorphous, many time sarcomas are classified as an uncertain type. Advances in immunohistochemistry, as well as the utility of novel markers such as TFE3, TLE1, MyoD1, and MUC4, have aided pathologists in classifying these soft tissue tumors. This discussion will cover the key facts and statistics about soft tissue tumors and what role IHC plays in these difficult diagnoses.
Watch Now

Mapping the Pituitary Cell Atlas with Multiomics

To gain insight into the immense complexity of biological structures such as the brain, it is imperative that investigators take an integrative approach that employs multi-omic technology and data. For instance, a complex neurological structure like the pituitary, which is considered the “master gland” of the endocrine system, regulates vital physiological functions, including growth, sexual maturation, reproduction, and lactation. A detailed characterization of pituitary cell populations and their underlying gene regulatory programs is needed to better understand cellular functions in this structurally complex tissue—just the right spot for some cutting-edge multi-omic studies.
Watch Now

Spotlight

resources